A Phase 1/2 Safety Study of Intratumourally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers
This study evaluates the intratumoural administration of escalating doses of a novel,
experimental drug, INT230-6. The study is being conducted in patients with several types of
refractory cancers including those at the surface of the skin (melanoma, head and neck,
lymphoma, breast) and tumours within the body such (pancreatic, colon, liver, lung, etc.).
Sponsor also plans to test INT230-6 in combination with anti-PD-1 antibodies.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society